15

2026y01m

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

January, 2026, AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IN ...

15

2025y12m

Belief BioMed's Gene Therapy Drug BBM-H901 for Hemophilia B Receives Orphan Drug Designation from Saudi FDA

Shanghai, China, December 15, 2025 — Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the Saudi Food and Drug Administration (FDA) has recently granted Orphan Drug ...

25

2025y11m

Belief BioMed Announces IND Clearance by NMPA for Cervix High-grade Squamous Intraepithelial Lesion Gene Therapy Candidate BBM-C101

​Shanghai, China, November 25, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of ...

20

2025y11m

BBM-H901 Makes Another Appearance in an Authoritative International Journal! Nature Medicine Published Latest Data on BBM-H901 for Hemophilia B

​Shanghai, China, November 20, 2025 — Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the data from the Phase 1/2 and Phase 3 (NCT05203679) clinical ...

14

2025y05m

Belief BioMed Announces Implied Clinical Trial Approval by NMPA for Parkinson's Disease Gene Therapy Candidate BBM-P002

Shanghai, China, May 14th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) implied approval of an Inv…

18

2025y04m

Belief BioMed Announces IND Clearance by NMPA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, April 18th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of an Investig…

10

2025y04m

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

Shanghai, China, April 10 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA)

27

2025y03m

Belief BioMed Announces IND Clearance by NMPA for Osteoarthritis Gene Therapy Candidate BBM-A101 Injection

Shanghai, China, March 27th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of an Investig…

05

2025y02m

Belief BioMed Announces IND Acceptance by NMPA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, February 5th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) acceptance of an Inves…

25

2025y01m

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, January 22th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigationa…